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Mechanisms of Action of Etanercept in Psoriasis
Jennifer K. Tan1, Abhishek Aphale1, Rama Malaviya1, Yvonne Sun1 and Alice B. Gottlieb2
Psoriasis is a chronic inflammatory disease of the skin affecting up to 2.5% of the world’s population. The scaly,
erythematous plaques characteristic of this papulosquamous disorder are likely triggered and maintained by
cytokines and chemokines manufactured by cells of the immune system. Overproduction of inflammatory
mediators, such as tumor necrosis factor-alpha (TNF-a) and IFN-g, results in a self-sustaining inflammatory
cascade, causing abnormal keratinocyte proliferation and differentiation. Therapeutic drug design targeting TNF
has led to the emergence of successful biologic agents, such as etanercept, in recent years. Despite extensive
clinical trials documenting efficacious clinical response to therapy, there is a paucity of data investigating the
molecular mechanisms by which etanercept modulates the improvement of psoriasis. This brief review
summarizes recent work investigating the in vivo actions of etanercept, including its effects on various cell
types, inflammatory pathways, gene activation, nuclear factor kappa B expression, and apoptosis. The anti-
inflammatory properties of etanercept reveal mechanisms by which a TNF blockade may result in the
improvement of psoriasis.
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INTRODUCTION
Psoriasis vulgaris is a chronic inflammatory disorder of the
skin affecting up to 2.5% of the world’s population
(Christophers, 2001). Clinically characterized by thickened,
erythematous plaques coated with scale, psoriasis is a
debilitating disease. Nearly one quarter of patients demon-
strate widespread cutaneous involvement and 25–34% have
joint disease (Gladman, 2004). The most common form is
plaque-type psoriasis, which frequently involves the appear-
ance of plaques on the trunk and extremities. Lesions are
often extensive and widely visible, resulting in an appreciable
amount of physical, emotional, psychological, and social
disability for patients (Krueger et al., 2001). There is currently
no cure for psoriasis and treatment options produce variable
response, in part, because disease pathogenesis is not
understood completely. Largely, traditional therapeutic
agents targeted abnormal keratinocyte proliferation and
differentiation or induced general immunosuppression, there-
by producing temporary improvement, partial response, or
serious adverse effects.
Following the demonstration that deneleukin difitox
(DAB389IL-2), a fusion protein that poisons IL-2 receptor-
expressing cells selectively without affecting keratinocytes
directly, cleared psoriasis (Gottlieb et al., 1995), the T cell,
rather than the keratinocyte, became the primary target for
therapeutic drug design. The subsequent investigation of
numerous biologic agents directed at receptors, cytokines,
and cells of the immune system produced agents with
improved safety and efficacy profiles, but have not produced
disease improvement in 100% of patients. This observation
suggests that the pathophysiology of psoriasis involves a
complex and only partially understood interplay between T
cells, antigen-presenting cells, keratinocytes, and the mole-
cules synthesized by these cells.
T cells influence disease pathogenesis through activation,
migration into the skin, and production of cytokines,
including tumor necrosis factor-a (TNF-a), IFN-g, and IL-2.
Although the precise cause of T-cell activation is unknown
currently, a type 1 immune response predominates in
psoriatic plaques (Lew et al., 2004). The IFN-g dependent
component of this pathway stimulates immediate activation
of signal transducer and activator of transcription (STAT-1)
with subsequent expression of primary (e.g. intercellular
adhesion molecule-1 [ICAM-1], mitogen-inducible gene
[MIG], IL-23) and secondary (e.g. inducible nitric oxide
synthase [iNOS], IL-8, interferon inducible protein [IP]-10)
response genes. Overexpression of TNF-a results in the
synthesis of pro-inflammatory cytokines (e.g. IL-1, IL-8)
and activation of the transcription factor nuclear factor kappa
B (NF-kB) (Lizzul et al., 2005). Antigen-presenting cells
such as dendritic cells (DCs) and macrophages infiltrate the
skin and become activated. Enhanced T-cell activation results
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directly from cellular interactions with antigen-presenting
cells and indirectly through IL-23 and IL-12, cytokines
produced by antigen-presenting cells (Oppmann et al.,
2000; Krueger, 2002). TNF-a and other cytokines trigger
abnormal keratinocyte proliferation and differentiation
resulting in the clinical features of psoriasis, and excess
production of TNF-a is at least partially responsible for the
development, proliferation, and maintenance of psioratic
lesions (Krueger, 2002).
The role of TNF and anti-TNF therapy in psoriasis
First isolated by Carswell et al. (1975), TNF-a is an
instrumental cytokine in processes involving immunity,
inflammation, cell growth and differentiation, and apoptosis.
Psoriatic lesions demonstrate elevated levels of TNF in all
layers of the epidermis, dermal blood vessels (Kristensen
et al., 1993; Ettehadi et al., 1994), and the synovial fluid of
patients with psoriatic arthritis (Partsch et al., 1997). Psoriatic
disease activity and severity correlates directly with circulat-
ing amounts of TNF (Mussi et al., 1997), and while initial
increases in TNF-a production may result from T cells, other
leukocytes also have the ability to produce TNF (Victor and
Gottlieb, 2002).
Ultimately, TNF-a may induce a positive feedback loop
through the induction of TNF mRNA in keratinocytes (Banno
et al., 2004), which is thought to result in disease propagation
via effects on immunocytes and keratinocytes. Increased
cellular infiltration in skin may result from the upregulation of
adhesion molecules (such as ICAM-1, P-selectin, and
I-selectin) and vasodilatory proteins (e.g. iNOS) and chemo-
kines (such as IL-8 and MIP3a). Increased production of pro-
inflammatory molecules (such as IL-1, IL-6, IL-8, and NF-kB)
by leukocytes and keratinocytes stimulates cellular activa-
tion, apoptosis, and further cytokine production. TNF-a also
has complex effects on inflammatory gene expression and
differentiation, which are often specific to the type of cell and
state of activation (Gottlieb et al., 2005).
TNF blockade results in disease improvement for many
patients; however, clinical resolution is not observed
uniformly with anti-TNF therapy. There are currently three
TNF inhibitors used in the treatment of psoriasis: the
monoclonal antibodies infliximab (Centocor, Horsham, PA)
and adalimumab (Abbott, Abbott Park, IL), and the recombi-
nant protein etanercept (Amgen, Thousand Oaks, CA). All
three agents are approved for the treatment of psoriatic
arthritis; however, only etanercept is approved currently in
the United States and Europe for moderate-to-severe psor-
iasis. TNF inhibitors are utilized extensively in the treatment
of rheumatoid arthritis, Crohn’s disease, and ankylosing
spondylitis; however, extensive in vivo analysis has been
hampered by the limited accessibility of target organs. Tissue-
specific anti-inflammatory effects induced by TNF inhibition
have been observed in synovial fluid sampling from patients
with rheumatoid arthritis, in which there was a decrease in
synovial CD68þ myeloid cells (tissue macrophages), T cells,
and angiogenesis-regulating cytokine mRNA production
(Tak et al., 1996). However, the extent to which these
findings can be applied to patients with psoriasis is unknown.
Anti-TNF agents are thought to exert their effects in
psoriasis by the prevention of cellular infiltration through the
downregulation of cellular and vascular adhesion molecules,
decreased production of cytokines, and interference with
T-cell presentation and activation. We have demonstrated
that an infliximab-induced TNF blockade reduced epidermal
thickness, normalized keratinocyte differentiation, and
decreased intraepidermal T-cell infiltration (Gottlieb et al.,
2003). However, these data did not reveal whether clinical
and histological improvement of psoriasis could be attributed
to effects on T cells, DCs, or both. Of the three TNF
inhibitors, etanercept is thought to antagonize and neutralize
TNF/lymphotoxin (LT) without depleting cells expressing
TNF. Therefore, it is an ideal agent to study when examining
the effects of a TNF blockade.
Safety and efficacy of etanercept in psoriasis
Etanercept, which became FDA-approved for psoriasis in
April of 2004, is a dimeric fusion protein consisting of soluble
TNF receptor fused to the Fc portion of human IgG. By
preventing interactions between TNF and its receptors,
etanercept neutralizes TNF activity. Approximately 33–49%
of patients achieve a 75% decrease in Psoriasis Area and
Severity Index (PASI) score successfully, which varies based
on the dose and frequency of administration (Leonardi et al.,
2003). Treatment has also been associated with improved
psychological and physical quality of life (Rapp and Feldman,
2004).
A recent integrated analysis of 933 patients treated with
etanercept in multiple randomized, double-blind, placebo-
controlled trials revealed a favorable safety profile. Etaner-
cept was generally well-tolerated, with the most commonly
reported adverse effects being headache and injection site
reaction. The rate of serious adverse effects was similar
among placebo and etanercept-treated patients, occurring in
1% and 1.2%, respectively (Gottlieb et al., 2006). Etanercept
was also found to be safe and efficacious in studies involving
patients with moderate-to-severe rheumatoid arthritis, mod-
erate-to-severe juvenile rheumatoid arthritis, psoriatic arthri-
tis, and ankylosing spondylitis. In light of the clinical
experience and safety profile of etanercept, there is great
interest to determine precisely how improvement of psoriatic
plaques is attained. We have sought to better understand the
molecular mechanisms of etanercept and summarize in this
review our recent work investigating its in vivo anti-
inflammatory properties. Using treatment with etanercept as
a means to explore the anti-inflammatory effects of a TNF
blockade, we hope to demonstrate the integral functions of
T cells, DCs, and particular inflammatory pathways in the
pathogenesis of psoriasis.
Common study design
Each of the following tissue-based investigations involved an
analysis of skin samples from 10 patients with severe plaque-
type psoriasis treated with etanercept at the University of
Medicine and Dentistry of New Jersey – Robert Wood
Johnson Medical School. Each study was based on the idea
that genes, transcription factors, and inflammatory cascades
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induced by TNF/LT should be suppressed by etanercept.
Although conducted independently, each study utilized the
same group of patients and skin samples. Patients received
25 mg etanercept administered subcutaneously twice weekly
for 24 weeks, which was the only FDA-approved dosage
regimen at the time of the study. After 1 and 3 months of
treatment, mean decreases in PASI of 29% and 57% were
noted, respectively. Of the 10 patients in this study, six
achieved a PASI 50 response after 3 months and PASI 75 after
6 months. These results are consistent with observed clinical
responses to etanercept therapy (Leonardi et al., 2003). The
investigations described subsequently involved clinical
examination, immunohistochemistry, flow cytometry, and
reverse transcriptase-PCR. Both clinicians and laboratory
personnel were blinded to each other’s outcome parameters
during the data collection phases and samples were
processed at both the University of Medicine and Dentistry
of New Jersey – Robert Wood Johnson Medical School and
The Rockefeller University.
TNF inhibition by etanercept downregulates multiple
inflammatory pathways (Gottlieb et al., 2005)
This comprehensive tissue-based analysis of histological
responses to etanercept treatment correlated the efficacy of
an anti-TNF agent with suppression of both inflammatory cell
infiltration and cytokine/chemokine gene production. There
were statistically significant decreases in both epidermal and
dermal T cell and DC counts after only 1 month of therapy,
although epidermal reductions were greater than dermal
decreases for both cell types. These changes were observed
before meaningful clinical improvement occurred. By 6
months, intraepidermal DC and T-cell counts decreased
by 95% and 74%, respectively. There was a statistically
significant decrease in neutrophils after only 1 month of
therapy. ICAM-1 expression in keratinocytes, but not dermal
blood vessels, was reduced by etanercept.
Table 1 lists numerous inflammatory gene products
induced by TNF-a (early products) and/or the type I
inflammatory pathway (IFN-g-related). Real-time reverse
transcriptase-PCR was employed to quantify the activity of
these genes in addition to selected myeloid and lymphocyte-
associated products. The results, summarized in Figure 1,
demonstrate two patterns of gene regulation observed with
etanercept treatment. Maximal suppression of IL-8 and IL-1b,
considered among the immediate transcriptional responses
induced by TNF, occurred as early as 1 month in responder
patients. Additionally, virtually all other gene products,
including MIP3a, IL-23, iNOS, and granzyme B, were
reduced at 1 month, preceding clinical response. Observed
reductions in cytokine and chemokine gene expression
demonstrate a direct interruption in IFN-g, TNF-a, and
IL-23/IL-12 mediated inflammatory cascades by etanercept.
Furthermore, decreased T cell, DC, and granulocyte infiltra-
tion may be attributed to reductions in chemokines, adhesion
proteins, and iNOS.
A multivariate U score, the RS, was used to evaluate
disease improvement with integrative parameters such as
epidermal thickness and other histological markers of disease
severity. Subsequently, we correlated the RS score with gene
expression at 1 month, with results listed in Table 1. At this
initial time point, improvement of psoriasis correlated most
highly with reductions in several type 1 products (STAT-1, IL-
23, MIG, IL-8, iNOS) as well as IL-1 and IL-8. Observed
reductions in IL-8, IP-10, and MIP3a mRNA expression may
account for decreased infiltration of neutrophils, T cells, and
DCs, respectively. This is supported by the fact that decreased
inflammatory gene expression generally preceded and was
more substantial than reductions in leukocyte infiltration.
Interestingly, the RS correlated more robustly with a
reduction in epidermal DCs than T cells. Because iNOS-
producing CD11cþ myeloid DCs are greatly increased in
psoriatic lesions (Gottlieb et al., 2005), further analysis
regarding the pattern of protein expression was completed.
Response to etanercept correlated with a decrease in the
expression of iNOS within CD11cþ cells after 1 month of
treatment. After 3 and 6 months of therapy, expression of
TNF-induced IL-23p19 mRNA was also reduced in DCs.
Furthermore, CD83, a marker for mature/activated DCs, was
noted to be absent or greatly reduced after 3 months of
treatment. These decreases suggest that DCs may become
less activated with etanercept treatment and may therefore
occupy a more substantial role in the pathophysiology of
psoriasis than previously thought. Analysis of the expression
of transcription factor NF-kB in psoriasis further substantiates
this hypothesis.
Expression of NF-jB in psoriatic skin is downregulated
with response to etanercept treatment (Lizzul et al., 2005)
Among the downstream effectors induced by TNF are the Rel/
NF-kB proteins, which have a well-defined role in immunity,
inflammation, cell-cycle regulation, and protection against
apoptosis (Barnes and Karin, 1997). NF-kB is a heterodimer
consisting of p50 and p65 components, which remains
dormant in the cytoplasm until dissociation from its inhibitory
protein, IkB. It is activated by a large group of heterogeneous
stimuli, including various cytokines, oxidants, viruses, and
components of the immune system. Degradation of IkB
permits the nuclear translocation of NF-kB, where it serves
as a transcription factor for an extensive number of
Table 1. Genes induced by TNF (left) and/or IFN
through the type I inflammatory pathway (right)
Early TNF-induced
genes r
Type I pathway genes
(induced/regulated by
IFN-c) r
IL-1b 0.70 IL-23 0.72
IL-8 0.77 IL-8 0.77
MIP3a 0.65 STAT-1 0.69
IL-6 0.06 MIG 0.78
iNOS 0.83 iNOS 0.83
IP-10 0.79
Also shown is the correlation (r) of mRNA level with RS score at 1 month
Adapted with permission from Gottlieb et al. (2005).
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pro-inflammatory cytokines, chemokines, enzymes, adhesion
molecules, and receptors. In psoriasis, NF-kB activation may
contribute to disease pathogenesis through its ability to
promote the transcription of TNF-a, IL-1b, IL-2, iNOS, IFN-g,
IL-12, ICAM-1, and vascular adhesion molecule-1 among
other immunologic proteins. Interestingly, TNF-a both
activates and is stimulated by NF-kB, suggesting a potential
role for NF-kB in a TNF-mediated positive feedback loop in
psoriasis (Banno et al., 2004).
We recently utilized immunohistochemistry to character-
ize the nuclear expression of phosphorylated RelA/p65 in
skin from patients with psoriasis. Phosphorylation of RelA/
p65 is required for transcriptional activation of NF-kB. In
comparison with skin from healthy volunteers, patients with
500 1200
1000
800
600
400
200
0 0
40
80
120
160
IL-1
IFN
MIP3IL-8
IL-6 IL-23 p19
iNOSMIGSTAT 1
IP-10 CD83
Granzyme B
r =0.91
MMP12
IL-12/IL-23 p40
400
300
200
100
0
600
400
200
0
200
150
100
50
0
250
50
40
30
20
10
0
40
30
20
10
0
40
30
30
25
15
5
20
20
10
10
0 0
30 80 8
4
IL-1
STAT-1
IL-12p40
–4
–8
–10 –5 0 5
Pathway score
10
0
R
es
po
ns
e 
sc
or
e
60
40
20
0
25
15
5
20
10
0
30
25
15
5
20
10
0
0 0
10
5
15
20
25 7
6
5
4
3
2
1
BL NL
P =0.026
P =0.32
P =0.021
P =0.32
P =0.06
P =0.02
P =0.18
P =0.18
P =0.18
P =0.02
P =0.03
P =0.0006
P =0.0005P =0.007
P =0.15
P =0.03
P =0.15
P =0.001
P =0.0004
P =0.001
P =0.001
P =0.04
P =0.09
P =0.03
P =0.05
P =0.36 P =0.038
P =0.0001
P =0.00006
P =0.001
P =0.04 P =0.02
P =0.004
P =0.46
P =0.007
P =0.03P =0.01
P =0.13 P =0.13
P =0.008
P =0.03
P =0.02
P =0.12
P =0.019
P =0.036
BL LS 1 month 3 months 6 months BL NL BL LS 1 month 3 months 6 months BL NL BL LS 1 month 3 months 6 months
BL NL BL LS 1 month 3 months 6 monthsBL NL BL LS 1 month 3 months 6 monthsBL NL BL LS 1 month 3 months 6 months
BL NL BL LS 1 month 3 months 6 months BL NL BL LS 1 month 3 months 6 months BL NL BL LS 1 month 3 months 6 months
BL NL BL LS 1 month 3 monthsBL NL BL LS 1 month 3 months 6 months6 monthsBL NL BL LS 1 month 3 months 6 months
BL NL BL LS 1 month 3 months 6 months BL NL BL LS 1 month 3 months 6 months
N
or
m
a
liz
e
d 
to
 h
AR
P
Figure 1. Etanercept treatment reduces inflammatory gene expression. Expression of several inflammatory gene products is illustrated in nonlesional skin at
baseline (BL NL) and psoriatic skin at baseline (BL LS) and after 1, 3, and 6 months of treatment with etanercept. P-values indicate comparison with lesional
results. At 1 month, the combination of genes most highly correlated with the RS is shown (bottom right panel). The combined expression of IL-1, STAT-1, and
IL-23/IL-12 p40 mRNAs yields a correlation coefficient of r¼ 0.91, Po0.001. Reprinted with permission from Gottlieb et al. (2005).
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psoriasis demonstrated a 12-fold increase in the level of
activated nuclear phospho-RelA/p65 in non-lesional kerati-
nocytes. Additionally, a five-fold increase in epidermal
NF-kB expression was observed between non-lesional and
lesional skin from patients with psoriasis. This statistically
significant difference correlated with epidermal hypertrophy
and expression of the marker of abnormal keratinocyte
differentiation, K-16. These data, coupled with the high
levels of TNF-a found in psoriatic patients, suggest that NF-kB
may play a fundamental role in the disease pathogenesis.
This hypothesis is further supported by changes observed
in keratinocyte NF-kB expression with a TNF blockade.
Figure 2 demonstrates a dramatic decrease in epidermal
levels of phospho-RelA expressed in psoriatic plaques during
treatment with etanercept. Although significant decreases
were seen after 1 and 3 months of treatment, the greatest
reduction occurred after 6 months. Decreased NF-kB
expression correlated with reduction in epidermal thickness,
normalization of K-16, and clinical improvement. These data
substantiate that etanercept-mediated psoriasis clearance
in vivo may result in part from decreased epidermal NF-kB
activation; however, dermal expression was not formally
quantified in this study. Due to its central positioning in
inflammation and immunity, decreased expression of NF-kB
could result in significantly reduced production of TNF-a,
IFN-g, IL-12, and possibly IL-23 (Pahl, 1999). These effects
would parallel the decreases in cytokine mRNA gene
expression previously observed in response to etanercept
therapy.
Etanercept induces apoptosis of infiltrating DCs in psoriatic
plaques (Malaviya et al., 2006a)
Since programmed cell death is regulated intimately by TNF,
its receptors and NF-kB, apoptosis has been studied in several
subsets of patients treated with anti-TNF therapy. In patients
with rheumatoid arthritis, etanercept was observed to induce
apoptosis of synovial fluid macrophages and monocytes
within the circulating peripheral blood without affecting
T cells (Catrina et al., 2005). Similarly, infliximab has been
shown to induce apoptosis of T cells in the intestinal lamina
propria in patients with Crohn’s disease (Van den Brande
et al., 2003) and macrophages in the synovium of patients
with rheumatoid arthritis (Catrina et al., 2005). Collectively,
these data demonstrate that apoptosis within the target organ
may be an anti-inflammatory mechanism of action of TNF
antagonists. With regard to these findings, it is reasonable to
postulate that apoptosis may occur in psoriasis patients
treated with etanercept, and may in part explain decreased
leukocyte infiltration into plaques after etanercept treatment.
Immunohistochemistry using antibodies to active caspase-
3 was employed to detect apoptotic cells in the same
psoriatic plaques used in our previous studies. Results
revealed that etanercept induced apoptosis of infiltrating
dermal cells in the plaques of only those patients who
achieved PASI 75 after 24 weeks of treatment. The greatest
amount of apoptosis was observed after 1 month of treatment,
which preceded normalization of histological parameters of
response, such as inflammatory cell infiltrate, epidermal
thickness, and K-16 expression. Meaningful clinical response
was also attained at a later time point (3 months). Although
increased apoptosis still occurred in plaques after 3 and 6
months of treatment, it decreased substantially after 1 month,
probably due to a decrease in the susceptible population.
Sequential section analysis revealed that a majority of
apoptotic cells were CD11cþ myeloid DCs, suggesting that
early occurrence of DC apoptosis may account for subse-
quently observed downregulation in IL-23 and TNF-a
dependent pathways. Furthermore, as DCs are well-known
T-cell activators, their apoptosis may interrupt the T-cell-
mediated component of psoriasis. These data introduce
apoptosis as an alternate mechanism by which etanercept
may reduce inflammatory cell numbers, in addition to the
previously discussed effects on leukocyte inflammatory genes
expression, production of chemotactic factors, and expres-
sion of keratinocyte ICAM-1. Of note, apoptosis was not
detected in circulating T cells or monocytes.
This is not the first report of programmed cell death
occurring within psoriatic plaques in response to treatment.
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Figure 2. Etanercept downregulates expression of nuclear factor kappa B
(NF-jB) in psoriatic plaques. (a) Graphic representation of the average
number of keratinocytes (left) expressing phosphorylated NF-kB/p65 and the
average epidermal thickness (right) at baseline and after 1, 3, and 6 months of
treatment with etanercept. Statistical significance of Po0.01 is denoted by an
asterisk (*). (b) Representative images from patient biopsy samples collected at
corresponding time points. Immunohistochemical analysis demonstrates an
overexpression of NF-kB in psoriatic plaques at baseline. There is a striking
reduction of epidermal phosphorylated NF-kB/p65 after 1, 3, and 6 months of
therapy with etanercept. Arrows denote positive cells demonstrating nuclear
staining. Reprinted with permission from Lizzul et al. (2005).
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Clinical improvement has correlated with plaque apoptosis in
association with a number of therapeutic agents, including
therapy with narrow band ultraviolet light (Coven et al.,
1997), psoralen plus ultraviolet A light (Coven et al., 1999),
and 6-thioguanine (Coven et al., 1996). Interestingly, therapy
with the aforementioned DAB389IL-2, a chimeric toxin
targeting IL-2 receptor expressing cells, also induces apop-
tosis of DCs and T cells in psoriatic plaques (Holder et al.,
1999). Alefacept, originally postulated to induce apoptosis of
CD45ROþ memory T cells, appears to affect both T cells and
DCs in vivo (Tan J, Salahuddin K, Gottlieb AB, Sun Y, Lipets I,
Magliocco M, et al. Clinical response to alefacept treatment
correlates with late-onset apoptosis of infiltrating dermal cells
in psoriatic plaques. Presented at Psoriasis: From Gene to
Clinic, 3 December 2005, London). Recently, infliximab was
observed to induce apoptosis of lymphocytes in the skin and
circulating peripheral blood of a patient with psoriasis
(Malaviya et al., 2006b). Although T-cell apoptosis has been
the suggested therapeutic mechanism by which many of the
aforementioned therapies for psoriasis result in clinical
improvement, the data discussed here suggest that the
apoptotic depletion of DCs may also be necessary for disease
improvement.
Infiltrating dermal DCs, T cells, neutrophils and endothelial
cells express NF-kB in psoriatic plaques at baseline
In an effort to identify the cell phenotype overexpressing
NF-kB at baseline and therefore possibly most affected by
etanercept therapy through an NF-kB-mediated pathway, we
recently performed sequential section analysis utilizing
immunohistochemistry. Sequential skin samples from a
responder patient were stained with antibodies to NF-kB
and CD3, CD11c, CD31, or elastase to evaluate T cells, DCs,
endothelial cells, and neutrophils, respectively. The protocols
used in our initial investigations were followed (Lizzul et al.,
2005; Malaviya et al., 2006b) and selected positive findings
are depicted in Figure 3.
Numerous keratinocytes and CD11cþ dermal DCs
exhibited increased expression of activated, nuclear NF-kB
in psoriatic plaques at baseline. Expression was not demon-
strated by all cells of either group. Additionally, T cells,
neutrophils, and endothelial cells demonstrated an upregula-
tion of activated, nuclear NF-kB in this patient (data not
shown). These cell types were appreciably less numerous
when compared to positive DCs and keratinocytes. There-
fore, in this patient, NF-kB appears to be broadly activated in
myeloid DCs, keratinocytes, neutrophils, endothelial cells,
and T cells although quantitatively there are differences
among cell types. This may occur because TNF differentially
activates gene expression in various cell types and results in
the selective activation of NF-kB. To investigate this
hypothesis, we are currently repeating this experiment
involving a larger number of patients.
If NF-kB is activated in DCs and expression is down-
regulated by etanercept therapy, a disruption in the balance
of pro- and anti-apoptotic proteins regulated by NF-kB may
account for DC apoptosis after 1 month of treatment.
Numerous keratinocytes and select CD3þ , CD31þ , and
elastaseþ cells also demonstrated an upregulation of NF-kB
at baseline but were not observed to become apoptotic in
response to etanercept, despite downregulation in NF-kB
expression. Several factors could contribute to this. Firstly,
discrete cells may express distinct forms of NF-kB, which
may activate different target genes (Barnes and Karin, 1997).
Variability in the intracellular balance of pro- and anti-
apoptotic proteins is also known to exist among cell types.
Expression of the anti-apoptotic protein Bcl-xL has been
observed diffusely throughout the epidermis in psoriasis
(Wrone-Smith et al., 1995), which may protect epidermal
cells from TNF-mediated apoptosis through the suppression
of the JNK signaling cascade (Papa et al., 2006). Finally,
keratinocytes may require the concomitant blockage of
NF-kB and an environment rich in TNF-a and IFN-g for
apoptosis to occur (Qin et al., 2001).
These results suggest fundamental similarities and differ-
ences in NF-kB activation by TNF in the pathogenic cells of
psoriasis. However, it is important to consider that we studied
activated NF-kB expression in the inflammatory infiltrate
from only one responder because of sparse availability of
tissue samples. Future evaluation involving additional
patients is needed to define more precisely the expression
of NF-kB in psoriasis. There is also utility to determine the
forms of NF-kB downregulated during etanercept treatment,
as this may provide further insight into the precise genes
targeted and could potentially lead to the discovery of a novel
treatment for psoriasis through a selective blockade of NF-kB.
TNF blockade by etanercept ‘‘tunes’’ pro-inflammatory
gene expression and reverses psoriatic phenotype
From these studies of 10 patients with moderate-to-severe
psoriasis treated with etanercept, several unifying concepts
concerning the in vivo effects of a TNF blockade emerge. The
NFB
100 m 100 m
CD11c
Figure 3. Dermal DCs demonstrate increased expression of NF-jB in
lesional plaques at baseline. Immunohistochemical analysis of sequential
sections from a representative patient using antibodies to NF-kB (left) and
CD11c (right) are depicted. Cell positivity was determined based on
morphology and location. Several CD11cþ myeloid dermal DCs are noted to
express NF-kB in psoriatic plaques at baseline (marked by corresponding
shapes). There is also a region in the deep dermis (center, unmarked)
demonstrating both positive NF-kB and CD11c staining. This suggests that
CD11cþ DCs may be selectively activated through an NF-kB-dependent
pathway mediated by TNF in psoriatic plaques. NF-kB activation was also
observed for CD3, CD31, and elastase positive cells (data not shown);
however, these cells were less numerous than positive DCs. Thus, NF-kB is
abundantly activated in myeloid DCs, keratinocytes, neutrophils, endothelial
cells, and T cells, but there are quantifiable differences among cell types
(Scale bar¼ 100 mm).
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summative effects of etanercept are summarized in Figure 4.
Rather than modulate disease improvement through a rapid,
direct effect on leukocytes and keratinocytes, etanercept
appears to ‘‘tune’’ pro-inflammatory genes. Although we know
that etanercept has an effect on NF-kB, genes are typically
controlled by multiple transcription factors that may or may
not be influenced by TNF inhibition. It is therefore unclear
whether etanercept affects NF-kB directly or through TNF.
Nevertheless, TNF-mediated inflammatory responses are not
simply turned off, as suggested by the image of a ‘‘blockade,’’
but rather slowly downregulated through effects on multiple
inflammatory pathways. Gradual decreases in inflammation
eventually achieve normalization of the epidermis. This model
supports the delayed and variable clinical response to therapy,
which typically occurs after 3–6 months of therapy.
NF-kB appears to play a central role in the pathogenesis of
psoriasis and likely affects keratinocytes, dermal DCs, T cells,
neutrophils, and endothelial cells diversely. It is upregulated
in each of these cells at baseline; however, there are
quantitative discrepancies among cell types. After as little
as 1 month of treatment, etanercept decreases NF-kB in
plaques and results in significant DC apoptosis. Early
apoptosis may result from an alteration in pro- and anti-
apoptotic proteins regulated by NF-kB in DCs. The unique
occurrence of apoptosis among only responder patients
implies that early interruption of DC activation and matura-
tion may be a critical event for disruption of a TNF-mediated
positive feedback loop. In addition, this fundamental
difference between responders and nonresponders may serve
as a predictor of clinical response to etanercept. In addition to
apoptosis, early reductions in CD11cþ DCs may lead to
decreased T-cell activation and the observed reductions in
IFN-g, TNF-a, and IL-23/IL-12 dependent inflammatory gene
expression. Further improvements in psoriasis may be
modulated through decreased iNOS protein expression in
CD11cþ cells, resulting in reduced nitric oxide production.
After 1 month of etanercept therapy, there are substantial
reductions in TNF-dependent gene expression for adhesion
proteins (ICAM-1, etc.) and chemotactic factors (IL-8 for
neutrophils, MIP-3a for DCs, and IP-10 for T cells), which
decrease further over time. Clinical improvement occurs in
conjunction with these reductions, but maximal reductions
in PASI occur after 6 months of treatment. Decreases in
leukocytes are also most pronounced at this time point.
Delayed reductions in chemokine production and keratino-
cyte ICAM-1 may account for the late reductions in
infiltrating leukocytes. Ongoing but decreased apoptosis
may account for an alternate mechanism leading to
decreased cellular infiltration. These effects may function
synergistically to cause the dramatic reductions in DC
numbers and activation observed towards the end of therapy
with etanercept. It may also explain why DC counts are
reduced further than T-cell counts.
CONCLUSIONS
The psoriatic cascade may begin with DC activation and
maturation, stimulating T-cell activation, which leads to a
predominant TH1 inflammatory response. Lymphocytes,
DCs, neutrophils, keratinocytes, and possibly other cells
produce additional cytokines, growth factors, and chemo-
kines that result in a cyclical pattern of inflammation and the
formation of psoriatic plaques. From gene studies and
histological analysis, we demonstrated that a TNF/LT block-
ade induced by etanercept interrupts this self-sustaining
derangement, reverses cutaneous inflammation, and pro-
motes plaque clearance. This is achieved by the down-
regulation of multiple inflammatory pathways dependent on
active IFN-g, TNF-a, NF-kB, and IL-23. TNF inhibition also
interferes with myeloid CD11cþ DC maturation and
emigration, T-cell activation and emigration, and neutrophil
emigration. We have also shown that uninvolved psoriatic
skin contains an increased level of activated, nuclear
phospho-RelA compared with normal volunteer skin, and
that within the epidermis of psoriatic plaques there is an
overexpression of phospho-RelA as compared to unaffected
skin. NF-kB, which is intimately associated with IFN-g, TNF,
and the production of IL-12 and 23 among other mediators of
inflammation and immunity, appears to play a central
function in the psoriatic cascade. Furthermore, because
dermal DCs are observed to overexpress phospho-RelA in
untreated lesional skin, become apoptotic with etanercept
treatment, and decrease substantially in number with
response to therapy, it may be concluded that these cells
play a more substantial role in the pathogenesis of psoriasis
than previously surmised. These investigations of the in vivo
mechanisms of action of etanercept in psoriatic plaques
provide novel insight into the molecular complexities of anti-
TNF therapy in psoriasis.
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Figure 4. TNF blockade ‘‘tunes’’ pro-inflammatory gene expression and
reverses psoriatic phenotype. Etanercept differentially affects immune cells,
blood vessels, and the epidermis, resulting in decreased inflammation and
epidermal normalization. Leukocyte infiltration is interrupted by a reduction
in chemotactic cytokines regulated by IFN-g, TNF-a, and IL-23. This effect
may be enhanced by the prevention of cellular adhesion and migration by
reductions in iNOS, adhesion proteins, and possibly VEGF. These results, in
conjunction with decreases in cytokine production, iNOS, NF-kB expression,
and possibly anti-apoptotic proteins, promote normalization of the epidermis.
There is decreased activation of NF-kB in epidermal and dermal cells, which
may result in the apoptosis of DCs and possibly other cell types. Decreased
DC counts and activation result in decreased T-cell activation. These effects
may collectively interrupt the self-sustaining cycle of inflammation and
account for plaque clearance.
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